沙西妥珠單抗

沙西妥珠單抗
单克隆抗体
种类	完整抗体
目標	腫瘤相關鈣信號轉導2（英语：TACSTD2）
臨床資料
商品名（英语：Drug nomenclature）	Trodelvy
其他名稱	IMMU-132, hRS7-SN-38, sacituzumab govitecan-hziy
AHFS/Drugs.com	Monograph
MedlinePlus	a620034
核准狀況	美 DailyMed: govitecan Sacituzumab govitecan;
懷孕分級	澳: D ; Contraindicated;
给药途径	Intravenous
ATC碼	L01FX17 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 加：处方药（℞-only）/ Schedule D; 歐：Rx-only; 美：处方药（℞-only）;
识别信息
CAS号	1491917-83-9
PubChem CID	91668186;
DrugBank	DB12893;
ChemSpider	none;
UNII	M9BYU8XDQ6;
KEGG	D10985;
ChEMBL	ChEMBL3545262;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID401335985 ;
化学信息
化学式	C76H104N12O24S
摩尔质量	1,601.79 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O;
	InChI InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1; Key:ULRUOUDIQPERIJ-PQURJYPBSA-N;

沙西妥珠單抗（全名應為沙西妥珠單抗-戈維替康，INN：Sacituzumab govitecan）用於治疗三陰性乳癌和尿道移型上皮細胞癌（英语：Transitional cell carcinoma）^[10] ^[8]。算是此後疾病的後線治療，用于癌症已扩散且其他治疗方法失败時^[11]。透过静脉注射给药^[12]。

常见副作用包括恶心、嗜中性白血球低下、腹瀉、疲倦、贫血、呕吐、禿頭、便秘、食欲不振、皮疹和腹痛^[11]。其他副作用包括可能不孕和过敏反应^[11]。孕期或哺乳期使用可能對婴儿有害^[13]。它是一种抗體-藥物複合體（英语：Antibody–drug conjugate），沙西妥珠單抗是針对腫瘤相關鈣信號轉導2（英语：TACSTD2）（TACSTD2，TROP-2）的單株抗體，與拓撲異構酶抑製劑（英语：Topoisomerase inhibitor）ー戈維替康的结合^[11] ^[12]。

沙西妥珠單抗于2020年在美国取得医疗使用許可^[11]。自2021年起，因供貨不足，在欧洲已停产^[14]。

参考文獻

^ ^1.0 ^1.1 Trodelvy. Therapeutic Goods Administration (TGA). 14 September 2021 [17 September 2021]. （原始内容存档于17 September 2021）.
^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. （原始内容存档于3 April 2022）.
^ Trodelvy sacituzumab govitecan 180 mg powder for injection vial. Therapeutic Goods Administration (TGA). [17 September 2021]. （原始内容存档于17 September 2021）.
^ TGA eBS - Product and Consumer Medicine Information Licence. [22 February 2022]. （原始内容存档于22 February 2022）.
^ AusPAR: Sacituzumab govitecan | Therapeutic Goods Administration (TGA). [24 November 2022]. （原始内容存档于24 November 2022）.
^ Trodelvy | Therapeutic Goods Administration (TGA). [24 November 2022]. （原始内容存档于24 November 2022）.
^ Summary Basis of Decision (SBD) for Trodelvy. Health Canada. 23 October 2014 [29 May 2022]. （原始内容存档于29 May 2022）.
^ ^8.0 ^8.1 Trodelvy- sacituzumab govitecan powder, for solution. DailyMed. [9 April 2021]. （原始内容存档于20 March 2021）.
^ Trodelvy EPAR. European Medicines Agency. 14 September 2021 [24 November 2021]. （原始内容存档于25 November 2021）.
^ FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments. U.S. Food and Drug Administration (FDA). 22 April 2020 [22 April 2020]. （原始内容存档于23 April 2020）. 本文含有此來源中屬於公有领域的内容。
^ ^11.0 ^11.1 ^11.2 ^11.3 ^11.4 Sacituzumab Govitecan-hziy Monograph for Professionals. Drugs.com. [9 October 2021]. （原始内容存档于28 June 2021）（英语）.
^ ^12.0 ^12.1 Sacituzumab govitecan. SPS - Specialist Pharmacy Service. 10 February 2016 [9 October 2021]. （原始内容存档于3 October 2021）.
^ Sacituzumab govitecan (Trodelvy) Use During Pregnancy. Drugs.com. [9 October 2021]. （原始内容存档于27 February 2024）（英语）.
^ Availability of Trodelvy for European triple negative breast cancer patients. www.europarl.europa.eu. [9 October 2021]. （原始内容存档于9 October 2021）（英语）.

延伸閱讀

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. The New England Journal of Medicine. February 2019, 380 (8): 741–751. PMID 30786188. S2CID 73489970. doi:10.1056/NEJMoa1814213 .
Weiss J, Glode A, Messersmith WA, Diamond J. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert Review of Anticancer Therapy. August 2019, 19 (8): 673–679. PMID 31398063. S2CID 199518147. doi:10.1080/14737140.2019.1654378.

外部連結

Sacituzumab govitecan. ADC Review.
Sacituzumab govitecan. National Cancer Institute.
Clinical trial number NCT01631552 for "Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers" at ClinicalTrials.gov
Clinical trial number NCT02574455 for "ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT)" at ClinicalTrials.gov
Clinical trial number NCT03547973 for "Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer" at ClinicalTrials.gov
醫學主題詞表（MeSH）：Sacituzumab govitecan

[Trodelvy_APM_summary-1] 1.0 ^1.1 Trodelvy. Therapeutic Goods Administration (TGA). 14 September 2021 [17 September 2021]. （原始内容存档于17 September 2021）.

[2] Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. （原始内容存档于3 April 2022）.

[3] Trodelvy sacituzumab govitecan 180 mg powder for injection vial. Therapeutic Goods Administration (TGA). [17 September 2021]. （原始内容存档于17 September 2021）.

[4] TGA eBS - Product and Consumer Medicine Information Licence. [22 February 2022]. （原始内容存档于22 February 2022）.

[5] AusPAR: Sacituzumab govitecan | Therapeutic Goods Administration (TGA). [24 November 2022]. （原始内容存档于24 November 2022）.

[6] Trodelvy | Therapeutic Goods Administration (TGA). [24 November 2022]. （原始内容存档于24 November 2022）.

[7] Summary Basis of Decision (SBD) for Trodelvy. Health Canada. 23 October 2014 [29 May 2022]. （原始内容存档于29 May 2022）.

[Trodelvy_FDA_label-8] 8.0 ^8.1 Trodelvy- sacituzumab govitecan powder, for solution. DailyMed. [9 April 2021]. （原始内容存档于20 March 2021）.

[Trodelvy_EPAR-9] Trodelvy EPAR. European Medicines Agency. 14 September 2021 [24 November 2021]. （原始内容存档于25 November 2021）.

[FDA_PR-10] FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments. U.S. Food and Drug Administration (FDA). 22 April 2020 [22 April 2020]. （原始内容存档于23 April 2020）. 本文含有此來源中屬於公有领域的内容。

[AHFS2021-11] 11.0 ^11.1 ^11.2 ^11.3 ^11.4 Sacituzumab Govitecan-hziy Monograph for Professionals. Drugs.com. [9 October 2021]. （原始内容存档于28 June 2021）（英语）.

[SP2021-12] 12.0 ^12.1 Sacituzumab govitecan. SPS - Specialist Pharmacy Service. 10 February 2016 [9 October 2021]. （原始内容存档于3 October 2021）.

[Preg2021-13] Sacituzumab govitecan (Trodelvy) Use During Pregnancy. Drugs.com. [9 October 2021]. （原始内容存档于27 February 2024）（英语）.

[14] Availability of Trodelvy for European triple negative breast cancer patients. www.europarl.europa.eu. [9 October 2021]. （原始内容存档于9 October 2021）（英语）.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[9]

[8]

[10]

[11]

[12]

[13]

[14]